Status:
COMPLETED
Financial Difficulty in Patients With Blood Cancer
Lead Sponsor:
UNC Lineberger Comprehensive Cancer Center
Collaborating Sponsors:
Boston University
The Leukemia and Lymphoma Society
Conditions:
Chronic Lymphocytic Leukemia
Multiple Myeloma
Eligibility:
All Genders
18-99 years
Brief Summary
This is a hypothesis-driven, observational, cross-sectional, multi-site study of the financial difficulties experienced by patients undergoing treatment for multiple myeloma (MM) and chronic lymphocyt...
Detailed Description
The primary and secondary objectives of the study: PRIMARY OBJECTIVES: To estimate the proportion of individuals with MM and/or CLL who report experiencing financial difficulty in the past 12 months...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- PATIENT ELIGIBILITY CRITERIA
- Patients must have current diagnosis of chronic lymphocytic leukemia (CLL) or multiple myeloma (MM)
- Patients' medical records must be available to the registering institution
- Eligible patients must have been prescribed drug-based anticancer therapy, whether administered orally or by infusion, within the prior 12 months. Specifically, eligible patients are those who:
- Are presently being treated with infused or orally-administered anticancer therapy, OR
- Completed infused or orally-administered anti-cancer therapy in the past 12 months, OR
- Were prescribed infused or orally-administered anticancer therapy within the prior 12 months yet chose to forego treatment
- Not currently enrolled in a clinical trial in which drug is supplied by the study
- Patients with psychiatric illness or other mental impairment that would preclude their ability to give informed consent or to respond to the telephone survey are not eligible
- Patients must be able to read and comprehend English or Spanish
- SITE ELIGIBILITY CRITERIA
- Intent to complete the Practice Survey
- Access to patient medical records: Registering institution must have access to patient medical records, either on site or via request from other institutions, if recruiting patients at a site (as medical abstraction is required for collecting study data).
- Sites seeking to enroll Spanish- speaking patients must have Spanish speaking staff on site or through the use of a translation service to be able to conduct the informed consent discussion in Spanish.
- PHYSICIAN ELIGIBILITY CRTERIA
- The physician currently treats patients with chronic lymphocytic leukemia (CLL) and/or multiple myeloma (MM).
- The physician is a treating physician at a site which has opened this protocol (LCCC 2063) and/or a site which opened the Alliance protocol (A231602CD; ClinicalTrials.gov Identifier: NCT03870633). Eligible physicians do not need to have their own patients enrolled onto this protocol.
Exclusion
Key Trial Info
Start Date :
January 27 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 26 2025
Estimated Enrollment :
218 Patients enrolled
Trial Details
Trial ID
NCT05212233
Start Date
January 27 2022
End Date
February 26 2025
Last Update
September 26 2025
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
University Of Alabama At Birmingham
Birmingham, Alabama, United States, 25448
2
Mayo Clinic Cancer Center
Phoenix, Arizona, United States, 85054
3
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia, United States, 31405
4
LSU Health Baton Rouge-North Clinic
Baton Rouge, Louisiana, United States, 70805